Last $66.22 USD
Change Today -0.31 / -0.47%
Volume 9.2M
MDT On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

710 Medtronic Parkway

Minneapolis, MN 55432

United States

Phone: 763-514-4000

Fax:

ulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity, and urologic and gastrointestinal disorders. The following are the principal products offered by the company’s Neuromodulation business: Neurostimulation Systems for Chronic Pain: Neurostimulation therapy for chronic pain uses a neurostimulator to deliver mild electrical impulses to the spinal cord, which act to block pain signals from the brain. The company has a portfolio of neurostimulation systems in the industry, including rechargeable and non-rechargeable devices and a selection of leads used to treat chronic back and/or limb pain. Its portfolio of products includes pain neurostimulation systems with SureScan MRI Technology, including the RestoreSensor (rechargeable) SureScan MRI, with its proprietary AdaptiveStim technology. Other products include the RestoreULTRA (rechargeable), RestoreADVANCED (rechargeable), and PrimeADVANCED (non-rechargeable) neurostimulation systems. Implantable Drug Infusion Systems: The SynchroMed II Implantable Infusion System delivers small quantities of drug directly into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke. Deep Brain Stimulation (DBS) Systems: DBS uses a neurostimulator to deliver mild electrical pulses to precisely targeted areas in the brain. DBS is approved in various countries worldwide for the treatment of the disabling symptoms of essential tremor, Parkinson's disease, refractory epilepsy (outside the U.S.), severe, treatment-resistant obsessive-compulsive disorder (approved under a Humanitarian Device Exemption (HDE) in the U.S.), and chronic, intractable primary dystonia (approved under a HDE in the U.S.). The company’s family of Activa Neurostimulators for DBS includes Activa SC (single-channel primary cell), Activa PC (dual channel primary cell), and Activa RC (dual channel rechargeable). Gastroenterology and Urology Systems: Sacral neuromodulation uses InterStim, a neurostimulator, to help control the symptoms of overactive bladder, (non-obstructive) urinary retention, and chronic fecal incontinence. The InterStim system consists of a thin wire lead and a neurostimulator. After a trial stimulation period, the system is implanted under the skin in the upper buttock and delivers mild electrical pulses to stimulate the sacral nerves, which are involved in the control of bladder and bowel function. Enterra Therapy is the only gastric electrical stimulation therapy approved in the U.S. (under a HDE), Europe, and Canada for use in the treatment of intractable nausea and vomiting associated with gastroparesis. The system, which contains a small neurostimulator and two leads, stimulates the smooth muscles of the lower stomach. Customers: The primary medical specialists who use the company’s pain management and movement disorder products are neurosurgeons, neurologists, pain management specialists, anesthesiologists, physiatrists, and spinal surgeons. The primary medical specialists who use its gastroenterology and urology products are urologists, urogynecologists, gastroenterologists, and colorectal surgeons. Competition: The company’s primary competitors in this business are Boston Scientific; St. Jude; Allergan, Inc.; Uroplasty, Inc.; and Astellas Pharma, Inc. Surgical Technologies The company’s Surgical Technologies business develops, manufactures, and markets products and therapies to treat diseases and conditions of the ear, nose, and throat (ENT) and certain neurological disorders. In addition, this business develops, manufactures, and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus, and orthopedic surgeries. The company’s Advanced Energy business includes products in the emerging field of advanced energy surgical incision technology, as well as the haemostatic sealing of soft tissue and bone. The following are the principal products offered by its Sur

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT:US $66.22 USD -0.31

MDT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.59 USD -0.10
Allergan Inc/United States $168.21 USD -1.76
Astellas Pharma Inc ¥1,601 JPY +17.00
Becton Dickinson and Co $113.70 USD -1.31
Covidien PLC $90.85 USD -0.75
View Industry Companies
 

Industry Analysis

MDT

Industry Average

Valuation MDT Industry Range
Price/Earnings 22.4x
Price/Sales 3.8x
Price/Book 3.4x
Price/Cash Flow 19.5x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.